−13.63USD
−61.23 MUSD
7.16 MUSD
3.65 M
About Assembly Biosciences, Inc.
Sector
CEO
Jason A. Okazaki
Headquarters
South San Francisco
Website
Employees (FY)
65
Founded
2005
ISIN
US0453962070
FIGI
BBG000R62Q06
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ASMB is 13.00 USD — it has increased by 0.62% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Assembly Biosciences, Inc. stocks are traded under the ticker ASMB.
Assembly Biosciences, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
ASMB stock is 4.84% volatile and has beta coefficient of 0.75. Check out the list of the most volatile stocks — is Assembly Biosciences, Inc. there?
One year price forecast for Assembly Biosciences, Inc. has a max estimate of 36.00 USD and a min estimate of 36.00 USD.
ASMB earnings for the last quarter are −3.24 USD whereas the estimation was −2.82 USD which accounts for −14.89% surprise. Estimated earnings for the next quarter are −2.82 USD. See more details about Assembly Biosciences, Inc. earnings.
Assembly Biosciences, Inc. revenue for the last quarter amounts to 6.25 M USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 1.56 M USD.
Yes, you can track Assembly Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
ASMB stock has fallen by 9.41% compared to the previous week, the month change is a 10.08% rise, over the last year Assembly Biosciences, Inc. has showed a 1.25% increase.
ASMB net income for the last quarter is −10.96 M USD, while the quarter before that showed −14.42 M USD of net income which accounts for 23.98% change. Track more Assembly Biosciences, Inc. financial stats to get the full picture.
Today Assembly Biosciences, Inc. has the market capitalization of 70.84 M, it has increased by 6.67% over the last week.
No, ASMB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ASMB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Assembly Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 65.00 employees. See our rating of the largest employees — is Assembly Biosciences, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Assembly Biosciences, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Assembly Biosciences, Inc. stock shows the sell signal. See more of Assembly Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Assembly Biosciences, Inc. future price: according to them, ASMB price has a max estimate of 36.00 USD and a min estimate of 36.00 USD. Read a more detailed Assembly Biosciences, Inc. forecast: see what analysts think of Assembly Biosciences, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Assembly Biosciences, Inc. EBITDA is −64.20 M USD, and current EBITDA margin is −896.22%. See more stats in Assembly Biosciences, Inc. financial statements.